Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI

Mirum Pharmaceuticals, Inc. today announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with...

Related Keywords

Toronto ,Ontario ,Canada ,Netherlands ,Bettina Hansen ,Binitam Kamath ,Study Group ,Exchange Commission ,Drug Administration ,Alagille Syndrome Alliance ,Nasdaq ,Mirum Pharmaceuticals Inc ,Twitter ,Global Alagille Alliance ,Instagram ,Linkedin ,European Commission ,Product Service ,Alagille Syndrome Treated ,Staff Physician ,Senior Associate Scientist ,Sick Children ,Pam Vig ,Clinical Biostatistics ,Breakthrough Therapy ,Fat Soluble Vitamin ,Mirum Pharmaceuticals ,Private Securities Litigation Reform Act ,